A diagnosis of hormone receptor-positive (HR+) breast cancer indicates that estrogen and/or progesterone hormone receptors are found in the cancer cells.1 If the breast cancer cells have a normal amount of HER2 on their surface, the cancer cells are called HER2 negative (HER2-).1,2 An HR+, HER2- diagnosis can require a complex treatment regimen tailored to an individual patient, that may include hormone therapy, chemotherapy or a combination of these.3 HR+, HER2- breast cancer is the most common subtype of breast cancer, accounting for about 70% of breast cancer cases.4,5
The complex and evolving treatment landscape for locally advanced or metastatic HR+, HER2-breast cancer poses a challenge to community oncologists, who are tasked with ensuring the tolerability and adherence of patients to their treatment regimens. Difficult dosing schedules and side effect profiles of oral anti-cancer therapies require working knowledge of a rapidly growing body of medical literature.
Funding and support provided by Lilly Oncology. VV-OTHR-US-DEL-0992 © Lilly USA, LLC 2022. All rights reserved.
ACCC has engaged experts through a vodcast series from CANCER BUZZ TV, focusing on specific issues regarding treatment adherence to oral therapies, treatment-related side effects, patient education, and financial barriers for patients with HR+, HER2- breast cancer.
Tune-in as our expert discusses how and when to screen patients, and then connect them to available resources to better support patients’ financial needs.
Explore this list of curated, nationally available materials to support patients receiving oral therapies for HR+, HER2- breast cancer.
VV-OTHR-US-DEL-0992
For more information on this project, please contact the ACCC Provider Education department.
©2022. Association of Community Cancer Centers. All rights reserved. No part of this production may be reproduced or transmitted in any form or by any means without written permission.